（来源：新华日报） □ 本报记者 万小珍 通讯员 王燕 12月17日上午，常州市第一人民医院内科诊室，市民张立陪同83岁父亲就诊。经过父亲本人授权后，一 声"滴"响，他手机屏上跳出父亲过去5年完整就医轨迹：1次胆囊手术记录、6种长期服用药物、12份检 查报告。这些曾分散在不同医院档案袋里的健康信息，现在被归集成一份完整电子档案，一目了然。 这个全新的就医场景，得益于常州在全省率先推行的"一人一档一码"服务，"把每个人的健康轨迹存入 云端，实现随时查看。"常州市卫生健康委信息处处长许辛夷介绍，服务依托全市全民健康信息平台， 为每位居民建立一份终身电子健康档案，涵盖门诊、住院、检验、检查、处方等全量医疗数据。截至目 前，这项服务已覆盖全市500万居民。 从被动治病到主动预防，AI为居民画出"健康全息画像"。市民苏惠在被诊断为桥本甲状腺炎后，一度焦 虑不安。系统中"AI数字人"基于她的全部健康数据，生成一份综合分析报告：逐项解读指标、分析病情 发展趋势、提供用药注意事项，并量身定制包括饮食调整、复查计划在内的生活方式建议。"它像一位 24小时在线的'贴心医生助理'，解释得比我想问的还详细。"苏惠说。 这个"AI数字 ...

Core Insights - Changzhou has launched a "digital intelligence" upgrade for resident health records, being the first in the province to implement a "one person, one file, one code" service, aimed at creating a comprehensive electronic health record for each resident [1][2] Group 1: Health Data Integration - The city has integrated health data from various medical institutions, resulting in the collection of 5 million resident health records, allowing citizens to access their complete medical history across public healthcare facilities [2][3] - Residents can easily query their health records through the "My Changzhou APP," enhancing the convenience of medical consultations [2][3] Group 2: Health Monitoring and Prevention - The new service includes a "health holographic portrait" feature that provides residents with insights into their health status and potential risk factors, enabling proactive health management [2][3] - The system offers personalized intervention suggestions based on big data analysis, shifting the focus from passive treatment to active prevention [2][3] Group 3: AI Integration - An AI digital assistant has been introduced to assist residents in analyzing their health status, interpreting medical reports, and managing chronic diseases, providing tailored advice on medication, diet, and lifestyle [3][4] - The AI digital assistant has been described as a "personal doctor," offering detailed explanations and customized follow-up plans to alleviate patient anxiety [3][4] Group 4: Privacy and Security - Residents have control over their privacy settings, allowing them to restrict access to their health records, which can be shared with healthcare providers through a scanning authorization process [3][4] Group 5: Future Developments - Changzhou plans to expand the "one person, one file, one code" service by incorporating more innovative features, including AI algorithms for comprehensive health management across prevention, screening, diagnosis, treatment, and rehabilitation [4]

Core Viewpoint - Mindray Medical (300760) has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International and JPMorgan as joint sponsors [1] Company Overview - Mindray Medical is a leading global medical device company, holding a top position in both market capitalization and industrial revenue within the Chinese medical device industry [1] - The company ranks 23rd among the world's top medical device companies and is the only Chinese enterprise in the top 30 [1] - Mindray has developed a comprehensive product matrix covering various clinical scenarios, with six product categories ranking in the global top three and nine categories leading in China [1] Business Model and Strategy - Mindray is the only company among the top 30 medical device firms that spans multiple product lines, including in vitro diagnostics, life information and support, medical imaging, minimally invasive surgery, and minimally invasive intervention [1] - The company is accelerating its transition to a sustainable growth model driven by a flow-based business (reagents, high-value consumables, and digital services), focusing on an ecosystem centered around equipment, IT, and AI [1] - Mindray is a leader in the field of medical digitalization, possessing the largest hardware ecosystem globally and the most valuable data resources, having successfully launched several medical large models [1] Market Growth Potential - The global medical device market is expected to continue growing, increasing from $456.6 billion in 2020 to $1,157.6 billion by 2035 [1] - As the second-largest medical device market globally, China's market is projected to grow to 1,813.4 billion RMB by 2035, driven by the expansion of grassroots medical services, the popularization of chronic disease management, and government support for innovation and device upgrades [1]

Core Insights - The "AI + Healthcare" forum at the Boao Forum for Asia highlighted significant opportunities and challenges in integrating AI into the healthcare sector [1][3] - Experts emphasized the need for a flexible regulatory framework that adapts to rapid technological advancements while balancing risk and innovation [3][4] Group 1: Opportunities in AI Healthcare - AI has immense potential in personalized medicine and improving service accessibility, with capabilities to rapidly integrate vast amounts of information, such as in medical imaging analysis [3] - Clinical applications of large medical models are already aiding in treatment and decision-making, with future developments aiming to create digital twin life forms to optimize surgical planning [3] Group 2: Challenges in AI Healthcare - The need for a regulatory framework that evolves with technology was stressed, with discussions on responsibility allocation in cases of AI diagnostic errors [3] - Experts called for enhanced communication between traditional medical professionals and AI specialists to improve AI accuracy and mitigate risks [3] Group 3: Collaborative Efforts - There is a consensus on the necessity for technological innovation, flexible regulation, and international cooperation to ensure the positive development of "AI + Healthcare" for broader societal benefit [4]

Summary of the Conference Call for 易都科技 (Yidu Technology) Company Overview - 易都科技 (Yidu Technology) focuses on AI-driven solutions in the healthcare sector, particularly in medical data management and intelligent diagnosis systems. The company has made significant strides in integrating AI into various medical processes and has established partnerships with numerous healthcare institutions. Key Points Financial Performance - The company reported a net loss reduction of 38.9% year-on-year, with operating expenses (OPEX) decreasing by 23% and accounting for 10 percentage points less of total revenue, indicating improved operational efficiency and profitability potential [2][3][4] - Adjusted EBITDA for the fiscal year 2025 reached 39 million yuan, reflecting a substantial growth of 25.6% year-on-year [3][15] Product Development and AI Integration - 易都科技 has developed a CO pilot product matrix aimed at doctors, leveraging an AI platform that integrates various large models, including Deep Sick, to enhance the entire medical process from pre-diagnosis to post-treatment [2][4] - The company plans to invest between 80 million to 100 million yuan in large model development over the next three years, anticipating a doubling of adjusted EBITDA by fiscal year 2026 [4][13] Applications in Oncology - The company has focused on oncology, establishing over 120 new diagnostic and treatment scenarios in top-tier specialized institutions [6][10] - The "小肝人" (Little Liver) AI diagnostic tool, led by a prominent academician, has been implemented in various hospitals, showcasing its effectiveness in liver cancer treatment [6][10][26] AI Services and Adoption - AI services provided by 易都科技 allow doctors to create customized solutions using a no-code toolchain, with 43% of hospital staff utilizing these AI diagnostic assistants, resulting in 26,000 patient services within two months [7][9] - The company has seen a 15% year-on-year increase in hospital orders, indicating growing acceptance and demand for its AI solutions [7] International Expansion - 易都科技 is involved in the MSC home mobile nursing project in Singapore, which supports remote monitoring of discharged patients through the Doctor Body app [9][27] - The company aims to expand its presence in Southeast Asia and the Middle East, capitalizing on the lower level of AI integration in these regions [27] Challenges and Strategic Focus - The main challenges faced include technical issues related to AI hallucination rates and budget constraints from B-end clients, which require a focused strategy on core customers and projects [17][20] - The company emphasizes the need for specialized medical models to address the complexities of healthcare data, differentiating itself from general AI models [18] Future Outlook - 易都科技 expects to achieve financial sustainability by 2027, with growth driven by its three main business segments [27] - The company is also exploring slow disease management and plans to expand its product offerings based on physician needs and market demands [29] Competitive Landscape - The healthcare AI market is competitive, with major players like Alibaba, JD, and Huawei. 易都科技 differentiates itself through its deep understanding of diseases and high precision in AI applications [24][25] Conclusion - 易都科技 is positioned for growth with its innovative AI solutions in healthcare, strategic investments in product development, and a focus on expanding its market presence both domestically and internationally. The company is addressing challenges head-on while maintaining a clear vision for future profitability and service enhancement.